Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan-Feb;66(1):7–30.
Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology. 2012 Jan;60(1):199–215.
Whitaker NJ, Glenn WK, Sahrudin A, Orde MM, Delprado W, Lawson JS. Human papillomavirus and Epstein Barr virus in prostate cancer: Koilocytes indicate potential oncogenic influences of human papillomavirus in prostate cancer. Prostate. 2013 Feb 15;73(3):236–41.
Zambrano A, Kalantari M, Simoneau A, Jensen JL, Villarreal LP. Detection of human polyomaviruses and papillomaviruses in prostatic tissue reveals the prostate as a habitat for multiple viral infections. Prostate. 2002 Dec 1;53(4):263–76.
Kundu SD, Lee C, Billips BK, Habermacher GM, Zhang Q, Liu V, Wong LY, Klumpp DJ, Thumbikat P. The toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate. 2008 Feb 1;68(2):223–9.
Sutcliffe S, Nevin RL, Pakpahan R, Elliott DJ, Cole SR, De Marzo AM, Gaydos CA, Isaacs WB, Nelson WG, Sokoll LJ, Zenilman JM, Cersovsky SB, Platz EA. Prostate involvement during sexually transmitted infections as measured by prostate-specific antigen concentration. Br J Cancer. 2011 Aug 23;105(5):602–5.
Singh N, Hussain S, Kakkar N, Singh SK, Sobti RC, Bharadwaj M. Implication of high risk human papillomavirus HR-HPV infection in prostate cancer in Indian population--a pioneering case-control analysis. Sci Rep. 2015 Jan 16;5:7822.
Bae JM. Human papillomavirus 16 infection as a potential risk factor for prostate cancer: an adaptive meta-analysis. Epidemiol Health. 2015 Feb 11;37:e2015005.
Brenes Bermúdez FJ, Alcántara Montero A. [Early detection or screening in the prevention of prostate cancer?]. Semergen. 2016 Mar 5. pii:S1138-3593(16)00046-0.
De Visschere PJL, Briganti A, Fütterer JJ, et al. Role of multiparametric magnetic resonance imaging in early detection of prostate cancer. Insights into Imaging. 2016;7(2):205–14.
Javali TD, Dwivedi DK, Kumar R, Jagannathan NR, Thulkar S, Dinda AK. Magnetic resonance spectroscopy imaging-directed transrectal ultrasound biopsy increases prostate cancer detection in men with prostate-specific antigen between 4-10 ng/mL and normal digital rectal examination. Int J Urol. 2014 Mar;21(3):257–62.
Petrillo A, Fusco R, Setola SV, Ronza FM, Granata V, Petrillo M, et al. Multiparametric MRI for prostate cancer detection: performance in patients with prostate-specific antigen values between 2.5 and 10 ng/mL. J Magn Reson Imaging. 2014 May;39(5):1206–12.
Perdonà S, Di Lorenzo G, Autorino R, Buonerba C, De Sio M, Setola SV, et al. Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection. Urol Oncol. 2013 Aug;31(6):761–5.
Ghai S, Haider MA. Multiparametric-MRI in diagnosis of prostate cancer. Indian J Urology : IJU : J Urological Society of India. 2015;31(3):194–201.
Engelbrecht MR, Jager GJ, Laheij RJ, Verbeek AL, van Lier HJ, Barentsz JO. Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol. 2002;12:2294–302.
Lee SH, Park KK, Choi KH, Lim BJ, Kim JH, Lee SW, et al. Is endorectal coil necessary for the staging of clinically localized prostate cancer? Comparison of non-endorectal versus endorectal MR imaging. World J Urol. 2010 Dec;28(6):667–72.
Kim BS, Kim T-H, Kwon TG, Yoo ES. Comparison of Pelvic Phased-Array versus Endorectal Coil Magnetic Resonance Imaging at 3 Tesla for Local Staging of Prostate Cancer. Yonsei Medical J. 2012;53(3):550–6.
Wang L, Mazaheri Y, Zhang J, Ishill NM, Kuroiwa K, Hricak H. Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy. Radiology. 2008 Jan;246(1):168–76.
Oto A, Yang C, Kayhan A, Tretiakova M, Antic T, Schmid-Tannwald C, Eggener S, Karczmar GS, Stadler WM. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol. 2011 Dec;197(6):1382–90.
Hoeks CM, Hambrock T, Yakar D, Hulsbergen-van de Kaa CA, Feuth T, Witjes JA, et al. Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging. Radiology. 2013 Jan;266(1):207–17.
Kim JK, Hong SS, Choi YJ, Park SH, Ahn H, Kim CS, et al. Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J Magn Reson Imaging. 2005;22:639–46.
Roethke MC, Lichy MP, Jurgschat L, Hennenlotter J, Vogel U, Schilling D, et al. Tumor size dependent detection rate of endorectal MRI of prostate cancer--a histopathologic correlation with whole-mount sections in 70 patients with prostate cancer. Eur J Radiol. 2011 Aug;79(2):189–95.
Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA. Predictors of pathologic stage in prostatic carcinoma: the role of neovascularity. Cancer. 1994;73:678–87.
Buckley DL, Roberts C, Parker GJ, Logue JP, Hutchinson CE. Prostate cancer: evaluation of vascular characteristics with dynamic contrast enhanced T1-weighted MR imaging—initial experience. Radiology. 2004;233:709–15.
Bonekamp D, Jacobs MA, El-Khouli R, Stoianovici D, Macura KJ. Advancements in MR imaging of the prostate: from diagnosis to interventions Radiographics. Review. 2011 May-Jun;31(3):677–703.
Turnbull LW, Buckley DL, Turnbull LS, Liney GP, Knowles AJ. Differentiation of prostatic carcinoma and benign prostatic hyperplasia: correlation between dynamic Gd-DTPA-enhanced MRI and histopathology. J Magn Reson Imaging. 1999;9:311–6.
Rouviere O, Raudrant A, Ecochard R. olin-Pangaud C, Pasquiou C, Bouvier R, et al. Characterization of time-enhancement curves of benign and malignant prostate tissue at dynamic MRI. Eur Radiol. 2003;13:931–42.
Engelbrecht MR, Huisman HJ, Laheij RJ, Jager GJ, van Leenders GJ, Hulsbergen-Van De Kaa CA, et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology. 2003;229:248–54.
Padhani AR, MacVicar AD, Gapinski CJ, Dearnaley DP, Parker GJ, Suckling J, et al. Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imaging. Radiology. 2001;218:365–74.
Eis M, Els T, Hoehn-Berlage M, Hossmann KA. Quantitative diffusion MR imaging of cerebral tumor and edema. Acta Neurochir Suppl (Wien). 1994;60:344–6.
Eis M, Els T, Hoehn-Berlage M. High resolution quantitative relaxation and diffusion MRI of three different experimental tumors in rat. Magn Reson Med. 1995;34:835–44.
Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai T, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging. 1999;9:53–60.
Castillo M, Smith JK, Kwock L, Wilber K. Apparent diffusion coefficients in the evaluation of highgrade cerebral gliomas. AJNR Am J Neuroradiol. 2001;22:60–4.
Sato C, Naganawa S, Nakamura T, Kumada H, Miura S, Takizawa O, et al. Differentiation of non cancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging. 2005;21:258–62.
Hosseinzadeh K, Schwarz SD. Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magn Reson Imaging. 2004;20:654–61.
Chan I, Wells W 3rd, Mulkern RV, Mulkern RV, Haker S, Zhang J, et al. Detection of prostate cancer by integration of line-scan diffusion, T2-mapping and T2-weighted magnetic resonance imaging; a multichannel statistical classifier. Med Phys 2003;30:2390–2398.
Shimofusa R, Fujimoto H, Akamata H, Motoori K, Yamamoto S, Ueda T, et al. Diffusion-weighted imaging of prostate cancer. J Comput Assist Tomogr. 2005;29:149–53.
Tan CH, Wei W, Johnson V, Kundra V, Diffusion-weighted MRI. in the detection of prostate cancer: meta-analysis. AJR Am J Roentgenol. 2012 Oct;199(4):822–9.
Emad-Eldina S, Halima M, Metwallya L, Mahmoud Abdel-Azizb R. Diffusion-weighted MR imaging and ADC measurement in normal prostate, benign prostatic hyperplasia and prostate carcinoma. Egyptian J Radiology Nuclear Medicine Volume 45, Issue 2, June 2014, Pages 535–542.
Yağci AB, Ozari N, Aybek Z, Düzcan E. The value of diffusion-weighted MRI for prostate cancer detection and localization. Diagn Interv Radiol. 2011 Jun;17(2):130–4.
Haider MA, van der Kwast TH, Tanguay J, Evans AJ, Hashmi AT, Lockwood G, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol. 2007 Aug;189(2):323–8.
Brown TR, Kincaid BM, Ugurbil KNMR. chemical shift imaging in three dimensions. Proc Natl Acad Sci U S A. 1982;79:3523–6.
Panebianco V, Sciarra A, Ciccariello M, Lisi D, Bernardo S, Cattarino S, et al. Role of magnetic resonance spectroscopic imaging ([1H]MRSI) and dynamic contrast-enhanced MRI (DCE-MRI) in identifying prostate cancer foci in patients with negative biopsy and high levels of prostate-specific antigen (PSA). Radiol Med. 2010 Dec;115(8):1314–29.
Prando A, Kurhanewicz J, Borges AP. OliveiraEM Jr, Figueiredo E. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific anti-gen levels and prior negative biopsy findings: early experience. Radiology. 2005;236:903–10.
Testa C, Schiavina R, Lodi R, Salizzoni E, Tonon C, D'Errico A, et al. Accuracy of MRI/MRSI-based transrectal ultrasound biopsy in peripheral and transition zones of the prostate gland in patients with prior negative biopsy. NMR Biomed. 2010;23:1017–26.
Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology. 2005;234:804–14.
Coakley FV, Kurhanewicz F, Lu Y, Jones KD, Swanson MG, Chang SD, et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology. 2002;223:91–7.
Stamey TA, McNeal JE, Freiha FS, Redwine E. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol. 1988;139:1235–41.
Giannarini G, Crestani A, Rossanese M, Ficarra V. Multiparametric Magnetic Resonance Imaging Targeted Biopsy for Early Detection of Prostate Cancer: All That Glitters Is Not Gold! Eur Urol. 2017 Jan 13. pii: S0302-2838(17)30017-9.
McNeal JE, Villers AA, Redwine EA, Freiha FS. S tamey TA. Capsular penetration in prostate cancer: significance for natural history and treatment. Am J Surg Pathol. 1990;14:240–7.
KK Y, Scheidler J, Hricak H, Vigneron DB, Zaloudek CJ, Males RG, et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology. 1999;213:481–8.
Bloch BN, Furman-Haran E, Helbich TH, Lenkinski RE, Degani H, Kratzik C, et al. Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging-initial results. Radiology. 2007;245:176–85.
Bloch BN, Genega EM, Costa DN, Pedrosa I, Smith MP, Kressel HY, et al. Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI. Eur Radiol. 2012;22:2201–10.
Wang L, Zhang J, Schwartz LH, Eisenberg H, Ishill NM, Moskowitz CS, et al. Incremental value of multiplanar cross-referencing for prostate cancer staging with endorectal MRI. AJR Am J Roentgenol. 2007;188:99–104.
Catalá V, Vilanova JC, Gaya JM, Algaba F, Martí T. Multiparametric magnetic resonance imaging and prostate cancer: what's new? Radiologia. 2017 Feb 21. pii: S0033-8338(17)30006-1.
Salerno J, Finelli A, Morash C, Morgan SC, Power N, Schieda N, Haider MA. Multiparametric magnetic resonance imaging for pre-treatment local staging of prostate cancer: A Cancer Care Ontario clinical practice guideline. Can Urol Assoc J. 2016 Sep-Oct;10(9-10):E332–9.
De Visschere P, Lumen N, Ost P, Decaestecker K, Pattyn E, Villeirs G. Dynamic contrast-enhanced imaging has limited added value over T2-weighted imaging and diffusion-weighted imaging when using PI-RADSv2 for diagnosis of clinically significant prostate cancer in patients with elevated PSA. Clin Radiol. 2017 Jan;72(1):23–32.
Thestrup KC, Logager V, Baslev I, Møller JM, Hansen RH, Thomsen HS. Biparametric versus multiparametric MRI in the diagnosis of prostate cancer. Acta Radiol Open. h Aug 17;5(8):2058460116663046.
Ueno Y, Tamada T, Bist V, Reinhold C, Miyake H, Tanaka U, Kitajima K, Sugimura K, Takahashi S. Multiparametric magnetic resonance imaging: Current role in prostate cancer management. Int J Urol. 2016 Jul;23(7):550–7.
Turkbey B, Brown AM, Sankineni S, Wood BJ, Pinto PA, Choyke PL. Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer. CA Cancer J Clin. 2016 Jul;66(4):326–36. doi: 10.3322/caac.21333.
Amsellem-Ouazana D, Younes P, Conquy S, Peyromaure M, Flam T, Debre B, et al. Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. Eur Urol. 2005;47:582–6.
Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R, et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol. 2000;163:152–7.
Beyersdorff D, Taupitz M, Winkelmann B, Fischer T, Lenk S, Loening SA, et al. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology. 2002;224:701–6.
Bhatia C, Phongkitkarun S, Booranapitaksonti D, Kochakarn W, Chaleumsanyakorn P. Diagnostic accuracy of MRI/MRSI for patients with persistently high PSA levels and negative TRUS-guided biopsy results. J Med Assoc Thai. 2007;90:1391–9.
Cheikh AB, Girouin N, Colombel M, Marechal JM, Gelet A, Bissery A, et al. Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol. 2009;19:770–8. doi: 10.1007/s00330-008-1190-8
Cirillo S, Petracchini M, Della MP, Gallo T, Tartaglia V, Vestita E, et al. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours. Clin Radiol. 2008;63:871–9.
Franiel T, Stephan C, Erbersdobler A, Dietz E, Maxeiner A, Hell N, et al. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding - multiparametric MR imaging for detection and biopsy planning. Radiology. 2011;259:162–72.
Lattouf JB, Grubb RLIII, Lee SJ, Bjurlin MA, Albert P, Singh AK, et al. Magnetic resonance imagingdirected transrectal ultrasonography-guided biopsies in patients at risk of prostate cancer. BJU Int. 2007;99:1041–6.
Perrotti M, Ankem MK, Weiss RE, Epstein R, Decarvalho VS, Kattan M, et al. Endorectal MRI: adjunct to repeat biopsy in prostate cancer detection. The smart biopsy. J Urol. 2002;167:387.
Wetter A, Hubner F, Lehnert T, Fliessbach K, Vorbuchner M, Roell S, et al. Three-dimensional 1H-magnetic resonance spectroscopy of the prostate in clinical practice: technique and results in patients with elevated prostate-specific antigen and negative or no previous prostate biopsies. Eur Radiol. 2005;15:645–52.
Yao DF, DeWolf WC, Sanda MG, Bloch BN, Genega EM, Berry AM, et al. Increased positive yield of clinically significant prostate cancer with MRI prompted biopsies. J Urol. 2009;181(Suppl. 1):782–3.
Younes P, Zerbib M, Saighi D, Conquy S, Thiounn N, Flam T, et al. Interest of endorectal MRI for patients with a high risk of prostate cancer but negative sextant biopsies. Eur Urol. 2001;39:148.
Yuen JS, Thng CH, Tan PH, Khin LW, Phee SJ, Xiao D, et al. Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol. 2004;171:1482–6.
Heijmink SW, Fütterer JJ, Hambrock T, Takahashi S, Scheenen TW, Huisman HJ, et al. Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. Radiology. 2007 Jul;244(1):184–95.
Sciarra A, Panebianco V, Salciccia S, Osimani M, Lisi D, Ciccariello M, et al. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol. 2008 Sep;54(3):589–600.
Tamada T, Sone T, Higashi H, Jo Y, Yamamoto A, Kanki A, et al. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. AJR. 2011;197:664–70.
Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Cattarino S, Lisi D, et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res. 2010;16:1875–83.
Iwazawa J, Mitani T, Sassa S, Ohue S. Prostate cancer detection with MRI: is dynamic contrast-enhanced imaging necessary in addition to diffusion-weighted imaging? Diagn Interv Radiol. 2011;17:243–8.
Kitajima K, Kaji Y, Fukabori Y, Yoshida K, Suganuma N, Sugimura K. Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J Magn Reson Imaging. 2010;31:625–31.
Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging. 2007;25:146–52.
Vilanova JC, Barceló-Vidal C, Comet J, Boada M, Barceló J, Ferrer J, et al. Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer. AJR Am J Roentgenol. 2011 Jun;196(6):W715–22.
Destefanis P, Bosio A, De Maria C, Bisconti A, Cugiani A, Negro CLA, et al. Targeted needle re-biopsy of the prostate after combination of endorectal MRI (ENDOMRI) and magnetic resonance spectroscopy (MRS) in patients with atypical small acinar proliferation (ASAP). Eur Urol Suppl. 2009;8:354.
Fusco R, Sansone M, Petrillo M, Setola SV, Granata V, Botti G, et al. Multiparametric MRI for prostate cancer detection: Preliminary results on quantitative analysis of dynamic contrast enhanced imaging, diffusion-weighted imaging and spectroscopy imaging. Magn Reson Imaging. 2016 Sep;34(7):839–45.
Loffroy R, Chevallier O, Moulin M, Favelier S, Genson PY, Pottecher P, et al. Current role of multiparametric magnetic resonance imaging for prostate cancer. Quant Imaging Med Surg. 2015 Oct;5(5):754–64.
Sankineni S, Osman M, Choyke PL. Functional MRI in Prostate Cancer Detection. Biomed Res Int. 2014;2014:590638.
Hegde JV, Mulkern RV, Panych LP, Fennessy FM, Fedorov A, Maier SE, et al. Multiparametric MRI of Prostate Cancer: An Update on State-of-the-Art Techniques and Their Performance in Detecting and Localizing Prostate Cancer. J Magn Reson Imaging. 2013 May;37(5):1035–54.
de Rooij M, Hamoen EH, Witjes JA, Barentsz JO, Rovers MM. Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. Eur Urol. 2016 Aug;70(2):233–45.
Abd-Alazeez M, Ahmed HU, Arya M, Charman SC, Anastasiadis E, Freeman A, et al. The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level-can it rule out clinically significant prostate cancer? Urol Oncol. 2014;32. 45:e17–22.
Hamoen EH, de Rooij M, Witjes JA, Barentsz JO, Rovers MM. Use of the prostate imaging reporting and data system (PI-RADS) for prostate cancer detection with multiparametric magnetic resonance imaging: A diagnostic meta-analysis. Eur Urol. 2015;67:1112–21.
American College of Radiology. MR Prostate Imaging Reporting and Data System version 2.0. [Accessed Jan 2015]. from http://www.acr.org/Quality-Safety/Resources/PIRADS/
Chen H, Sutedjo J, Wang L, Yin X. Prostate Cancer Magnetic Resonance Spectroscopy Imaging at 1.5 and 3.0 T: A Meta-Analysis. Technol Cancer Res Treat. 2016 May 4.
Costa DN, Yuan Q, Xi Y, Rofsky NM, Lenkinski RE, Lotan Y, et al. Comparison of prostate cancer detection at 3-T MRI with and without an endorectal coil: A prospective, paired-patient study. Urol Oncol. 2016 Jun;34(6):255.e7-255.e13.
Baur AD, Daqqaq T, Wagner M, Maxeiner A, Huppertz A, Renz D, et al. T2- and diffusion-weighted magnetic resonance imaging at 3T for the detection of prostate cancer with and without endorectal coil: An intraindividual comparison of image quality and diagnostic performance. Eur J Radiol. 2016 Jun;85(6):1075–84.
Shah ZK, Elias SN, Abaza R, Zynger DL, DeRenne LA, Knopp MV, et al. Performance comparison of 1.5-T endorectal coil MRI with 3.0-T nonendorectal coil MRI in patients with prostate cancer. Acad Radiol. 2015 Apr;22(4):467–74.
Margolis DJA, Multiparametric MRI. for Localized Prostate Cancer: Lesion Detection and Staging. BioMed Research Int. 2014;2014:684127.
Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Fütterer JJ. European Society of Urogenital Radiology. ESUR prostate MR guidelines 2012. Eur Radiol. 2012 Apr;22(4):746–57.